Investor Relations
Stock Information
News & Events
Presentations and Publications
Financials
Corporate Governance
Shareholder Services

Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
08/10/17Neothetics Provides Business Update and Reports Second Quarter 2017 Financial Results
SAN DIEGO, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) provided a business update and reported financial results for the second quarter 2017. In July 2017, Neothetics announced that its Board of Directors unanimously approved plans to initiate a process to explore and review a range of strategic alternatives focusing on seeking an acquisition, business combination or partnership that will allow for it to maximize shareholder value from its remaining assets and cash reso... 
Download PDFPrinter Friendly Version
07/10/17Neothetics Announces Review of Strategic Alternatives
SAN DIEGO, July 10, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) announced today that its Board of Directors has unanimously approved plans to initiate a process to explore and review a range of strategic alternatives focusing on seeking an acquisition, business combination or partnership that will allow for it to maximize shareholder value from its remaining assets and cash resources. Neothetics has engaged Oppenheimer and Co., Inc.  to act as its exclusive financial advisor to the... 
Download PDFPrinter Friendly Version
06/26/17Neothetics Announces Top-Line Results for Phase 2 Proof-of-Concept Study of LIPO-202 for the Reduction of Submental Subcutaneous Fat
LIPO-202 did not show efficacy in the reduction of submental fat SAN DIEGO, June 26, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced top-line safety and efficacy results from its Phase 2 proof-of-concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat. LIPO-202 did not demonstrate improvement on any efficacy measurements or separation from placebo... 
Download PDFPrinter Friendly Version
05/11/17Neothetics Provides Business Update and Reports First Quarter 2017 Financial Results
SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today provided a business update and reported financial results for the first quarter 2017. “We are extremely pleased with the progress made during the quarter,” said Kim Kamdar, Ph.D., a member of Neothetics’ Operating Committee and Board of Directors.  “If approved, LIPO-202 could be the first non-ablative option for... 
Download PDFPrinter Friendly Version
05/04/17Neothetics to Provide a Business Update and Release First Quarter 2017 Financial Results Thursday, May 11th, 2017
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, announced today that it will provide a business update and release its first quarter 2017 financial results before the market opens on Thursday, May 11, 2017. To receive Neothetics' press releases and other investor information, please go to the Investor Relations page of the company's website at investors.neothetics.... 
Download PDFPrinter Friendly Version
04/05/17Neothetics Announces Issuance by USPTO of Eighth Patent Directed to LIPO-202 Lead Clinical Asset
SAN DIEGO, April 05, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced the issuance of U.S. Patent Number 9,597,531 by the United States Patent and Trademark Office (USPTO).  This patent is directed to specific methods of using LIPO-202 and other agents for the reduction of fat accumulation. The ’531 patent is expected to expire no earlier than the fourth quarter of 2031, e... 
Download PDFPrinter Friendly Version
03/29/17Neothetics to Present at the 16th Annual Needham Healthcare Conference
SAN DIEGO, March 29, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced that Susan A. Knudson, Neothetics’ Chief Financial Officer, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5th at 12:50 PM,  Eastern Time at the Westin Grand Central Hotel in New York City. To receive Neothetics' press releases and other investor information, please go to the Investor Relations page of the company's website at investors.neothetics.com and register fo... 
Download PDFPrinter Friendly Version
03/23/17Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results
SAN DIEGO, March 23, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today provided a business update and reported financial results for the fourth quarter 2016. “We are encouraged by our progress on our Phase 2 proof of concept trial for LIPO-202 in submental fat reduction and continue to expect top-line data in June 2017,” said Mr. Jeffrey M. Nugent, a member of Neothetics’ Operating Committee and Board of Directors. “We remain excited about the submental fat reduction market and ... 
Download PDFPrinter Friendly Version
03/20/17Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
SAN DIEGO, March 20, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced completion of subject enrollment for its Phase 2 proof of concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat.   “We are excited to announce the conclusion of enrollment in our first trial with LIPO-202 for the reduction of submental fat. We are encouraged by the strong inve... 
Download PDFPrinter Friendly Version
03/16/17Neothetics to Provide a Business Update and Release Fourth Quarter 2016 Financial Results Thursday, March 23, 2017
SAN DIEGO, March 16, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced that it will provide a business update and release its fourth quarter 2016 financial results before the market opens on Thursday, March 23, 2017.  To receive Neothetics' press releases and other investor information, please go to the Investor Relations page of the company's website at investors.neothetics.com and register for email alerts.   About Neothetics, Inc. Neothetics is a San Diego based cli... 
Download PDFPrinter Friendly Version